Adis Journals
Capture.JPG (61.3 kB)

Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use

Download (61.3 kB)
online resource
posted on 2020-03-08, 18:34 authored by Emma Deeks

Compliance with ethical standards

Funding: The preparation of this review was not supported by any external funding.

Conflicts of interest: Emma Deeks is an employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no conflicts of interest.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (, which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made

Additional information about this Adis Drug Review can be found here


Subcutaneous insulin glargine/lixisenatide [Suliqua® 100/33 and 100/50 (EU); Soliqua® 100/33 (USA)] is a titratable, fixed-ratio combination of a long-acting basal insulin analogue + a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to treat inadequately controlled type 2 diabetes (T2D) in adults. Once-daily insulin glargine/lixisenatide provided glycaemic control better than that of insulin glargine or lixisenatide in insulin-naive patients (when added to metformin) and better than that of insulin glargine in insulin-experienced patients (when used ± metformin) in phase 3 trials in adults with inadequately controlled T2D. It also had a beneficial effect on bodyweight and did not increase the frequency of hypoglycaemia versus insulin glargine. Insulin glargine/lixisenatide is generally well tolerated and offers the convenience of once-daily administration of two subcutaneous antihyperglycaemic agents. It is, therefore, a valuable option for improving glycaemic control in adults with T2D when this has not been provided by metformin alone or metformin + another oral antihyperglycaemic agent or + basal insulin.

© Springer Nature 2019; corrected publication 2019


Usage metrics

    Drugs & Therapy Perspectives


    Ref. manager